ALLIANCES (Otsuka) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Alliances Statement [Line Items]
Net product sales									$ 19,258	$ 17,702	$ 14,045
Alliance revenues									1,518	1,725	2,515
Total Revenues	$ 5,449	$ 5,254	$ 5,144	$ 4,929	$ 5,243	$ 4,922	$ 4,871	$ 4,391	20,776	19,427	16,560
Otsuka [Member]
Alliances Statement [Line Items]
Net product sales									1,814	1,670	1,501
Alliance revenues									7	2	604
Total Revenues									1,821	1,672	2,105
Cost of products sold - Oncology fee									299	304	299
Cost of products sold - Royalties									11	10	30
Cost of products sold - Cost of product supply									31	$ 30	$ 35
Otsuka [Member] | Oncology Territory [Member] | Sprycel and Ixempra [Member] | Annual net sales up to $400 million [Member]
Alliances Statement [Line Items]
Range of sales at which given percentage will be paid to alliance partner - maximum									400
Otsuka [Member] | Oncology Territory [Member] | Sprycel and Ixempra [Member] | Annual net sales between $400 and $600 million [Member]
Alliances Statement [Line Items]
Range of sales at which a given percentage will be paid to alliance partner - minimum									400
Range of sales at which given percentage will be paid to alliance partner - maximum									600
Otsuka [Member] | Oncology Territory [Member] | Sprycel and Ixempra [Member] | Annual net sales between $600 and $800 million [Member]
Alliances Statement [Line Items]
Range of sales at which a given percentage will be paid to alliance partner - minimum									600
Range of sales at which given percentage will be paid to alliance partner - maximum									800
Otsuka [Member] | Oncology Territory [Member] | Sprycel and Ixempra [Member] | Annual net sales between $800 million and $1 billion [Member]
Alliances Statement [Line Items]
Range of sales at which a given percentage will be paid to alliance partner - minimum									800
Range of sales at which given percentage will be paid to alliance partner - maximum									1,000
Otsuka [Member] | Oncology Territory [Member] | Sprycel and Ixempra [Member] | Annual net sales over $1 billion [Member]
Alliances Statement [Line Items]
Range of sales at which a given percentage will be paid to alliance partner - minimum									$ 1,000
United States, Japan and EU [Member] | Sprycel and Ixempra [Member] | Annual net sales up to $400 million [Member]
Alliances Statement [Line Items]
Percentage of net sales payable to alliance partner									65.00%
United States, Japan and EU [Member] | Sprycel and Ixempra [Member] | Annual net sales between $400 and $600 million [Member]
Alliances Statement [Line Items]
Percentage of net sales payable to alliance partner									12.00%
United States, Japan and EU [Member] | Sprycel and Ixempra [Member] | Annual net sales between $600 and $800 million [Member]
Alliances Statement [Line Items]
Percentage of net sales payable to alliance partner									3.00%
United States, Japan and EU [Member] | Sprycel and Ixempra [Member] | Annual net sales between $800 million and $1 billion [Member]
Alliances Statement [Line Items]
Percentage of net sales payable to alliance partner									2.00%
United States, Japan and EU [Member] | Otsuka [Member] | Sprycel and Ixempra [Member] | Annual net sales over $1 billion [Member]
Alliances Statement [Line Items]
Percentage of net sales payable to alliance partner									1.00%